Skip to main content
RECCE PHARMACEUTICALS LTD logo

RECCE PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · RCE ISIN · AU000000RCE5 LEI · 549300TKQWXKEHP10T28 ASX Manufacturing
Open in API
Filings indexed 685 across all filing types
Latest filing 2025-04-16 Capital/Financing Update
Country AU Australia
Listing ASX RCE

About RECCE PHARMACEUTICALS LTD

https://www.recce.com.au

Recce Pharmaceuticals Ltd is dedicated to the development and commercialization of a new class of synthetic anti-infectives designed to address the global challenge of antimicrobial resistance. The company's lead compound, RECCE® 327, is a broad-spectrum synthetic antibiotic engineered with a unique mechanism of action to combat hyper-mutating bacteria, including both Gram-positive and Gram-negative species. This technology is specifically formulated to maintain efficacy over repeated use, targeting critical medical needs such as sepsis, burn wound infections, and urinary tract infections. By utilizing a proprietary synthetic polymer-based platform, the company aims to disrupt bacterial cellular processes in a manner that prevents the development of resistance, providing a potential solution for multi-drug resistant pathogens.

Recent filings

Filing Released Lang Actions
Cleansing Notice 1 page 204.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'Cleansing notice under section 708A(5)(e) of the Corporations Act'. It discusses the issuance of new shares as part of a placement raising A$5.0 million, referencing compliance with sections of the Corporations Act related to disclosure exemptions. The content focuses on a capital raising event and the legal notice required for the issuance of shares without a disclosure document. There are no financial statements, earnings data, or management commentary present. The document is short (1606 characters) and serves as a formal announcement of a capital transaction rather than a full report or detailed financial disclosure. Therefore, it fits best under the category for Capital/Financing Update (CAP).
2025-04-16 English
RCE Investor Webinar Presentation 1 page 92.7KB
Investor Presentation Classification · 95% confidence The document is an ASX announcement about an upcoming investor webinar presentation. It includes details about the webinar date, registration link, topics to be covered, and mentions that presentation slides were previously released. There is no detailed financial report or substantive financial data included in the text. The document serves as an announcement and invitation for an investor presentation event rather than the presentation itself or a financial report. Therefore, the appropriate classification is Investor Presentation (IP). Given the clear context and content, confidence is high.
2025-04-14 English
Proposed issue of securities - RCE 9 pages 29.4KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and contains detailed information about a proposed securities issuance by Recce Pharmaceuticals Ltd. It includes specifics such as the number of securities to be issued, offer price, record dates, issue dates, and details about the placement and pro rata issue. The document is a formal announcement related to capital raising activities, specifically a placement and a pro rata issue of ordinary fully paid shares. There is no financial performance data, earnings information, or management discussion present. The content aligns with announcements about fundraising or capital structure changes. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial (13,690 characters), indicating it is not a brief notice but a full announcement of a capital raising event, not merely a report publication announcement or regulatory filing. Hence, the classification is CAP with high confidence.
2025-04-09 English
Placement and Entitlement Offer to Fund Phase III Trials 5 pages 268.4KB
Capital/Financing Update Classification · 100% confidence The document is an ASX announcement detailing a capital raising event by Recce Pharmaceuticals Ltd, including a placement and an entitlement offer to shareholders. It discusses the amount to be raised, the use of proceeds, offer price discounts, timetable for the offer, and participation details. There are no financial statements or detailed financial performance data included, nor is this a transcript, management report, or regulatory certification. The content focuses on financing activities and capital structure changes. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication notice but a substantive update on financing.
2025-04-09 English
Cleansing Notice - Entitlement Offer 3 pages 234.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement regarding a placement and entitlement offer by Recce Pharmaceuticals Limited. It references section 708AA(2)(f) of the Corporations Act, which relates to cleansing notices for share issues. The content details the terms of the placement and entitlement offer, the potential dilution effects, and compliance with relevant sections of the Corporations Act. There are no financial statements or detailed financial performance data included, nor is this a full report or earnings release. The document is a regulatory announcement about capital raising activities and compliance notices, not the actual capital raising report or financial results. Therefore, it fits best under Capital/Financing Update (CAP). The document length (7113 characters) and detailed content support this classification with high confidence.
2025-04-09 English
Equity Raising Presentation 48 pages 2.2MB
Capital/Financing Update Classification · 95% confidence The document is titled 'Equity Raising Presentation' and contains disclaimers, forward-looking statements, investment risk information, and a summary of the company's business and financial data. It is clearly prepared in connection with a placement and entitlement offer of new shares, indicating it is a presentation aimed at investors regarding a capital raising event. The content includes pro forma financial information and market data but does not contain actual financial statements or detailed financial results. The document is a presentation format, not a formal report like an annual or interim report. Therefore, it fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and financing activities.
2025-04-09 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.